CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Tzadok M(1), Uliel-Siboni S(2), Linder I(3). Request PDF on ResearchGate | CBD-enriched medical cannabis for intractable pediatric epilepsy. The current Israeli experience | Purpose. PURPOSE To describe the experience of five Israeli pediatric epilepsy clinics the effect of cannabidiol (CBD)-enriched medical cannabis on children with epilepsy. cannabis for intractable pediatric epilepsy The current Israeli experience.
Israeli CBD-enriched The medical current epilepsy: cannabis experience pediatric intractable for
Moreover, 66 per cent of them had also failed treatment with a ketogenic diet, vagal nerve stimulator implantation, or both. They all started treatment with cannabidiol-enriched medical cannabis between February and November and were treated for at least three months, with the average period being six months.
Seizure frequency was assessed by parental report during clinical visits. It was shown that cannabidiol treatment yielded a significant positive effect on seizure load, with 89 per cent of the cohort reporting a reduction in seizure frequency, with 18 per cent of them experiencing a reduction of between 75 and per cent. A small minority of five patients reported an aggravation of seizures which led to withdrawal of the treatment. Improvements in behaviour and alertness, language, communication, motor skills and sleep were all observed, while adverse reactions included somnolence, fatigue, gastrointestinal disturbances and irritability.
Further prospective, well-designed clinical trials using enriched cannabidiol medical cannabis are warranted. This offers further evidence supporting the potential benefits of this emerging epilepsy treatment option.
Abstract Purpose To describe the experience of five Israeli pediatric epilepsy clinics treating children and adolescents diagnosed as having intractable epilepsy with a regimen of medical cannabis oil. Methods A retrospective study describing the effect of cannabidiol CBD -enriched medical cannabis on children with epilepsy. The selected formula contained CBD and tetrahydrocannabinol at a ratio of Shanna Babalonis 8 Estimated H-index: Role of oxidative stress in Cannabis sativa-associated spermatotoxicity: Evidence for ameliorative effect of combined but not separate melatonin and vitamin C.
Isiaka Abdullateef Alagbonsi 3 Estimated H-index: Cannabinoids in treatment-resistant epilepsy: O'Connell 1 Estimated H-index: An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use.
Anastasia Suraev 6 Estimated H-index: The current status of artisanal cannabis for the treatment of epilepsy in the United States. Dustin Sulak 1 Estimated H-index: Other Papers By First Author.
Movement Disorder in Ataxia-Telangiectasia: Cannabidiol in patients with treatment-resistant epilepsy: Marsh University of Pennsylvania. Helen Cross University College London.
Therefore, according to our survey some participants would rather commence a CBD treatment even if not convinced about its efficacy than having patients using it without medical supervision. However, decision to commence CBD treatment is mainly made on individual case-by-case basis and most patients of our participants are treated outside of clinical trials.
Interestingly, a substantial number of answers about their country specific availability and regulations concerning reimbursement of CBD were contradictory. This is in line with the results of an US survey about the use of medical cannabis in cancer patients. This may indicate a further need for providing adequate information to health care providers given the striking differences between European countries in regulation, availability and covering of costs of medical cannabinoids in general and CBD in particular Given the widely differing practice concerning indications and limitations, choice of preparation, dosing and monitoring revealed by our survey, official guidelines for the use of CBD for epilepsy treatment appear to be advisable to harmonize and potentially improve its use.
There are several limitations concerning our survey. Since this was an open-access survey we cannot generate a response rate. We relied onto the participants to reply truthfully and thoroughly.
Numbers and percentages of CBD prescribers may be overestimated by a participation bias, that may be indicated by a substantial variation of responses between countries. Furthermore, we were not able to relate the numbers of participants to the total number of physicians that are treating children and adolescents with CBD in participating countries.
Therefore, we cannot to draw a representative picture for the extent of CBD use in participating countries. These aspects need to be considered when interpreting our findings. Nevertheless, we presented a broad overview of certain aspects of CBD use by European experts of childhood epilepsy and highlighted several limitations for its use in clinical practice.
CBD appears to be increasingly used by the participants of our survey, but the individual experience remains limited. There are diverse opinions about the use of CBD to treat epilepsy in children and adolescents and widely differing views on several aspects in managing the CBD treatment. KK conceptualized and designed the questionnaire, collected contact data, performed the survey, analyzed data and drafted the initial manuscript.
VA-A contributed to data collection, and revised the manuscript. AS-B contributed to the design of the questionnaire and revised the manuscript. JJ contributed to the design of the manuscript, contributed to the collection of contact data and revised the manuscript. All authors gave final approval of the version to be published. All authors agree to be accountable for the content of the work. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The Supplementary Material for this article can be found online at: Cannabinoids in the treatment of epilepsy: Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Evaluation of cannabidiol in animal seizure models by the epilepsy therapy screening program ETSP.
Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav EB Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients. CBD-enriched medical cannabis for intractable pediatric epilepsy: Cannabidiol in patients with treatment-resistant epilepsy: Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.
Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. Eur J Pain Lond Engl. Assessment of Israeli physicians' knowledge, experience and attitudes towards medical cannabis: PubMed Abstract Google Scholar. Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: Gloss D, Vickrey B.
Cochrane Database Syst Rev. Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome FIRES in the acute and chronic phases. Epilepsy Behav EB 8: Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Development of outcome criteria to measure effectiveness of antiepileptic therapy in children. Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod. Cannabinoids concentration variability in cannabis olive oil galenic preparations.
Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled cats. The influence of cannabidiol and delta 9-tetrahydrocannabinol on cobalt epilepsy in rats. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice. Impact of cannabis use on prefrontal and parietal cortex gyrification and surface area in adolescents and emerging adults.
The role of cannabinoids in neuroanatomic alterations in cannabis users. Biol Psychiatry Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Safety and side effects of cannabidiol, a Cannabis sativa constituent. Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: Anticonvulsant interaction of cannabidiol and ethosuximide in rats.
Consroe P, Wolkin A.
To describe the experience of five Israeli pediatric epilepsy clinics treating children and adolescents diagnosed as having intractable epilepsy with a regimen of. Abstract Purpose To describe the experience of five Israeli pediatric epilepsy clinics cannabis for intractable pediatric epilepsy The current Israeli experience of cannabidiol (CBD)-enriched medical cannabis on children with epilepsy. Publication - article. CBD-enriched medical cannabis for intractable pediatric epilepsy The current Israeli experience. Seizure, 35, ,